{
    "organizations": [],
    "uuid": "a29fb83e19ac3119f539b22d6df0fdf70677655a",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/08/business-wire-ovascience-to-host-fourth-quarter-and-fiscal-year-2017-financial-results-conference-call.html",
    "ord_in_thread": 0,
    "title": "OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that it will host a conference call at 4:30 p.m. ET on Thursday, March 15, 2018 to discuss fourth quarter and fiscal year 2017 financial results and provide a general corporate update.\nThe conference call may be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international callers five minutes prior to the start of the call and providing the passcode 7278292. A live webcast of the conference call will be available online from the Investors section of the Company’s website at www.ovascience.com .\nA replay of the conference call will be available from 7:00 p.m. ET on Thursday, March 15, 2018, through 11:59 p.m. ET on Thursday, March 29, 2018, and may be accessed by visiting OvaScience’s website or by dialing 1-888-843-7419 for U.S. callers and 1-630-652-3042 for international callers. The replay access code is 7278292#.\nAbout OvaScience℠\nOvaScience℠, Inc. (NASDAQ:OVAS) is a fertility company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC℠) cells – immature egg cells found within the outer ovarian cortex. OvaScience is developing the OvaPrime℠ treatment, which could increase a woman’s egg reserve and the OvaTure℠ treatment, a potential in vitro fertilization (IVF) treatment that could help a woman produce new fertilizable eggs without hormone injections. OvaScience’s AUGMENT℠ treatment, a fertility option designed to improve IVF success rates, is available in certain IVF clinics in Canada and Japan. OvaScience treatments are not available in the United States.\n###\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180308005339/en/\nOvaScience\nJennifer Viera, 617-420-8748\njviera@ovascience.com\nSource: OvaScience",
    "published": "2018-03-09T00:02:00.000+02:00",
    "crawled": "2018-03-09T03:47:33.026+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "waltham",
        "business",
        "wire",
        "nasdaq",
        "ovas",
        "company",
        "focused",
        "discovery",
        "development",
        "commercialization",
        "new",
        "treatment",
        "option",
        "woman",
        "family",
        "struggling",
        "infertility",
        "today",
        "announced",
        "host",
        "conference",
        "call",
        "et",
        "thursday",
        "march",
        "discus",
        "fourth",
        "quarter",
        "fiscal",
        "year",
        "financial",
        "result",
        "provide",
        "general",
        "corporate",
        "update",
        "conference",
        "call",
        "may",
        "accessed",
        "dialing",
        "caller",
        "international",
        "caller",
        "five",
        "minute",
        "prior",
        "start",
        "call",
        "providing",
        "passcode",
        "live",
        "webcast",
        "conference",
        "call",
        "available",
        "online",
        "investor",
        "section",
        "company",
        "website",
        "replay",
        "conference",
        "call",
        "available",
        "et",
        "thursday",
        "march",
        "et",
        "thursday",
        "march",
        "may",
        "accessed",
        "visiting",
        "ovascience",
        "website",
        "dialing",
        "caller",
        "international",
        "caller",
        "replay",
        "access",
        "code",
        "nasdaq",
        "ovas",
        "fertility",
        "company",
        "focused",
        "discovery",
        "development",
        "commercialization",
        "new",
        "treatment",
        "option",
        "woman",
        "family",
        "struggling",
        "infertility",
        "ovascience",
        "treatment",
        "based",
        "company",
        "proprietary",
        "technology",
        "platform",
        "leverage",
        "breakthrough",
        "discovery",
        "egg",
        "precursor",
        "cell",
        "immature",
        "egg",
        "cell",
        "found",
        "within",
        "outer",
        "ovarian",
        "cortex",
        "ovascience",
        "developing",
        "treatment",
        "could",
        "increase",
        "woman",
        "egg",
        "reserve",
        "treatment",
        "potential",
        "vitro",
        "fertilization",
        "ivf",
        "treatment",
        "could",
        "help",
        "woman",
        "produce",
        "new",
        "fertilizable",
        "egg",
        "without",
        "hormone",
        "injection",
        "ovascience",
        "treatment",
        "fertility",
        "option",
        "designed",
        "improve",
        "ivf",
        "success",
        "rate",
        "available",
        "certain",
        "ivf",
        "clinic",
        "canada",
        "japan",
        "ovascience",
        "treatment",
        "available",
        "united",
        "state",
        "view",
        "source",
        "version",
        "http",
        "ovascience",
        "jennifer",
        "viera",
        "jviera",
        "source",
        "ovascience"
    ]
}